Jerome Pierson, MD
Cardiovascular Disease · Sioux City, IANPI 1659345668
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 94 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 13.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $723 and has fallen 77.6% since, to $162 in 2025.
Across 94 payments — averaging $26.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$326
- Boston Scientific$224
- Actelion Pharmaceuticals US, Inc.$198
- Abbott$195
- Merck$182
- Johnson & Johnson$165
- plus $1K from 18 others
What the payments were for
- Food & beverage$2,460100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 17 | $326 |
| Boston Scientific | 7 | $224 |
| Actelion Pharmaceuticals US, Inc. | 4 | $198 |
| Abbott | 6 | $195 |
| Merck | 6 | $182 |
| Johnson & Johnson | 6 | $165 |
| Medtronic(2 entities) | 7 | $163 |
| Boehringer Ingelheim | 5 | $161 |
| E.r. Squibb & Sons, L.L.C. | 10 | $149 |
| Impulse Dynamics (USA) Inc. | 2 | $141 |
| Inari Medical, Inc. | 2 | $111 |
| Amgen | 4 | $67 |
| Conmed Corporation | 1 | $67 |
| Lexicon Pharmaceuticals, Inc. | 3 | $57 |
| Cardiovascular Systems Inc. | 2 | $48 |
| Novartis | 3 | $45 |
| Cardiva Medical, Inc. | 1 | $33 |
| AstraZeneca | 2 | $31 |
| Chiesi USA, Inc. | 1 | $21 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| Scpharmaceuticals Inc. | 1 | $18 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $16 |
| Irhythm Technologies, Inc. | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPTIMIZER$231
- VERQUVO$214
- CARDIOMEMS$110
- Resolute$103
How this compares
$2,460 in reported general payments places this provider in the 65th percentile of 142 cardiovascular disease providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 616 | $422,023 |
| XareltoRivaroxaban | 143 | $94,674 |
| Repatha SureclickEvolocumab | 65 | $42,366 |
| EntrestoSacubitril/Valsartan | 34 | $20,096 |
| FarxigaDapagliflozin Propanediol | 29 | $17,896 |
| BrilintaTicagrelor | 22 | $13,344 |
| Repatha SyringeEvolocumab | 19 | $10,535 |
| JardianceEmpagliflozin | 13 | $8,299 |
| Metoprolol Succinate | 630 | $6,004 |
| Diltiazem 12hr ErDiltiazem Hcl | 16 | $3,398 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 256 | $2,465 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 178 | $2,144 |
| Atorvastatin Calcium | 375 | $1,734 |
| Hydralazine Hcl | 261 | $1,603 |
| SotalolSotalol Hcl | 156 | $1,600 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $326 | $422,023616 claims |
| Johnson & JohnsonXarelto | $165 | $94,674143 claims |
| AstraZenecaFarxiga, Brilinta | $31 | $31,24051 claims |
| NovartisEntresto | $45 | $20,09634 claims |
| Boehringer IngelheimJardiance | $161 | $8,29913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 142 cardiovascular disease providers in Iowa.
Other cardiovascular disease in Sioux City
- Jon PeacockSioux City$3K
- Brian OlshanskyIowa City$219K
- Troy HounshellWest Des Moines$164K
- Enrico MartinWest Des Moines$113K
- Gursukhman Deep SidhuDavenport$60K
- Suzanne FeigofskyWest Des Moines$59K
- Tyler RasmussenCedar Rapids$37K
- Jennifer RobinsonIowa City$37K
- Matthew McMahonCedar Rapids$35K
- Craig StarkDes Moines$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.